Almost Day after day, this keeps going up.

What happens is there are lots of small shareholders selling out during the day who probably bought in when it was 25p due to being tipped in shares mag in July

THEN

At the end of each day there is a really BIG BUY that most people don't notice.
Usually at 16:29.

Next morning, it usually opens up 1/4p

This keeps on happening.

I finally freed up some cash this morning & bought some.
I wish that I had got in at 17p.

The big buyers obviously think that the new drugs will ge a great success.

What do you think?


It was also tipped again in October

SHARES MAGAZINE 30-10-2003

The gene therapy specialist has had a good run this year with shares rising to 28.2p in September. The company has two cancer therapies in the clinic for a range of indications as well as early-stage drugs for neurological disorders.

TroVax is a revolutionary cancer vaccine that works by delivering a gene to the cancer cell via a pox virus acting as a Trojan horse. The drug is in Phase II trials in colorectal cancer patients with the kudos of being sponsored by Cancer Research UK and trials in breast and renal cancer patients. MetXia has also received approval to enter Phase I/II trials for pancreatic cancer.

Investors should recall the high failure rate of cancer drugs such as British Biotechs Marimastat and remember that the risks are high, but Oxford Biomedica is well funded following a recent fundraising and there is still everything to play for.

http://www.wallstreetreporter.com/profiles/OxfordBioMedica.html

Buys outnumber sells by Six to one so far today.

Oncology Update looks good


http://www.uk-wire.com/cgi-bin/articles/200312180700124000T.html

I think I'll buy some more.

Over the last few days buys have outnumbered sells, there has been several 1M BUYS, including one this morning so the larger players are getting interested. News is looking good and if this Co is capitalised at around just 50m, the shares would soar on one entry to phase 3 trials. Many publications now rating a spec BUY too, now that they have good funding. Hold tight.

The buys are getting bigger.

The trading pattern has changed, the big buys used to happen at the end of the day to avoid attacting attention.

Now they happen any time of day because they can't avoid attacting attention anymore & there are so many more trades each day.

The spread has been closed, my broker offering Sell 22-Buy 22.19. This is to disscise what the big 22.125 trades are. IMHO they are buys

Loads of buying - wouldn't mind betting they're going to be written about for the weekend press, then we'll see a rise in price.

A bit of profit taking & THEN

large buys at the end of the day yet again.

Buys 1,211,588
Sells 643,140
Unknown 240,002

I heard this was a financial mag's newyear tip for yr - anyone know more?

AGAIN, another large buy late in the day.

Buy, Buy, Buy, Buy, Buy, Buy - so to flush out some sellers they put the price down and it worked, there were no sellers until late after the bid was reduced. Look at the ratio of buys to sells though! must have been tipped as I heard -see before

Tipped by Patrick Evershed, manager of the New Star Select Opportunities Fund, as his rising star for the year - money.telegraph.co.uk at the weekend.

AGAIN Large buys at end of day.

2.5 million shares bought at the end of the day.

Thanks for the info Scottie, - looking good then.

Taking off!

Hmmmmm, I think that there may be an announcement of more good news soon.

AFX News 16/01/04 07:28

Oxford BioMedica gets UK approval for its 3rd Phase II cancer trial for TroVax.

For info Seymore Pierce has started covering OXB with a buy note summarised below.

The company has a broad pipeline of products based upon three novel
platform technologies that have real potential to offer alternative therapies to existing/conventional drug treatments.

The company recently raised 20.4m via a 27 for 50 rights issue. The
company now has a significant cash pile, approximately 30m, with which to
develop the product pipeline and negotiate lucrative licensing deals in order
to accelerate towards profitability.

Our conservative NPV model demonstrates a base case investment thesis
supporting a price of 33p for TroVax and MetXia alone. This does not
include the 8p of cash on the balance sheet nor any value being ascribed to
the neurotherapy pipeline, which is expected to be a significant longer term
value driver.

We initiate coverage with the recommendation BUY

3.8% rise today.

Results due soon

http://moneyam.uk-wire.com/cgi-bin/articles/200401210700064556U.html

Drifted down a bit recently on thin trading.

Buying opportunity!